Company KaloBios Pharmaceuticals Inc Nasdaq
Equities
US48344T2096
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
03-08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Bob Atwill
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Ronald Barliant
BRD | Director/Board Member | 78 | 16-01-06 |
Rainer Boehm
BRD | Director/Board Member | 63 | 18-02-11 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 119,080,135 | 106,754,128 ( 89.65 %) | 0 | 89.65 % |
Company contact information
Humanigen, Inc.
830 Morris Turnpike 4th floor
07078, Essex County
+973 200 3100
http://www.humanigen.comSector
1st Jan change | Capi. | |
---|---|---|
-1.15% | 89.37B | |
+2.76% | 40.65B | |
-12.32% | 32.81B | |
+52.41% | 25B | |
-17.39% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- HGENQ Stock
- Stock
- Company KaloBios Pharmaceuticals Inc